Navigation Links
Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
Date:4/15/2011

SAN DIEGO, April 15, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a new analysis of an ongoing, long-term research study of the investigational drug metreleptin, an analog of the human hormone leptin, for the treatment of lipodystrophy. The study is being conducted by investigators from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH). Results from the analysis will be presented by Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals, at a late-breaking oral session on Sunday, April 17 at 7:55 a.m. PT at the 20th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists (AACE) in San Diego.

In the study, which has been ongoing for more than 10 years, researchers at the NIH are examining the effect of metreleptin on several metabolic abnormalities, including diabetes and hypertriglyceridemia (high levels of triglycerides in the bloodstream), in patients with rare inherited or acquired forms of lipodystrophy. Treatment with metreleptin resulted in robust reductions from baseline in both A1C and triglycerides. (A1C is a measure of average blood sugar over three months; triglycerides are the major form of fat stored in the body.) These improvements were apparent at four months and generally sustained for up to several years of treatment.

"Patients with rare forms of lipodystrophy are often affected by the disease early in life, are at high risk of acute and chronic complications and, currently, have very limited therapeutic options," said Dr. Weyer. "The results of our analysis reaffirm the potential of metreleptin as an important advance for people living with this chronic and often debilitating metabolic disease. We continue to work diligently toward bringing this potential
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015 Precyse, a leader in health information ... as part of its long term growth plan, the ... by investment firm Pamplona Capital Management (Pamplona).  Precyse,s board ... Partners and NewSpring Capital, have approved this corporate transaction. ... 5,000 healthcare facilities and systems across the ...
(Date:7/1/2015)... Research and Markets( ... "2015 Strategies in the Home/Self Testing Market" ... new 175-page report provides analysis of the major ... meters), pregnancy, ovulation, and occult blood. The report ... and competitive profiles. The growing economic ...
(Date:7/1/2015)... 2015 Dynatronics Corporation (the "Company") (NASDAQ: ... rehabilitation and physical therapy products, announced today that ... led by affiliates of Prettybrook Partners LLC (collectively, ... the healthcare industry. The financing provides Dynatronics with ... potential strategic acquisitions.  "We enthusiastically ...
Breaking Medicine Technology:Precyse Enters into Acquisition Agreement with Pamplona Capital Management 2Precyse Enters into Acquisition Agreement with Pamplona Capital Management 32015 Strategies in the Home/Self Testing Market 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 2Dynatronics Announces Completion Of $4,025,000 Private Placement Led By Prettybrook Partners 3
... YORK, Aug. 31 /PRNewswire/ Reportlinker.com announces that a ... catalogue: Hormone Replacement Therapy in ... 2017 http://www.reportlinker.com/p0254468/Hormone-Replacement-Therapy-in-Menopause---Pipeline-Assessment-and-Market-Forecasts-to-2017.html ... Assessment and Market Forecasts to 2017 ...
... 31 Reportlinker.com announces that a new market ... The Outlook for Pharmaceuticals In The ... http://www.reportlinker.com/p0285781/The-Outlook-for-Pharmaceuticals-In-The-Middle-East-And-North-Africa-To-2015.html ... social and demographic development is making the pharmaceutical ...
Cached Medicine Technology:Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 3Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 4Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 5Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 6Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 7Reportlinker Adds Hormone Replacement Therapy in Menopause - Pipeline Assessment and Market Forecasts to 2017 8Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 2Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 3Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 4Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 5Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 6Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 7Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 8Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 9Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 10Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 11Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 12Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 13Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015 14
(Date:7/2/2015)... ... 2015 , ... Denver-based SlimGenics Weight Control Centers, the leader ... 14 on ColoradoBiz magazine’s Top 100 Woman-Owned Companies list. ColoradoBiz compiles the exclusive ... award identifies outstanding woman-owned businesses that demonstrate excellence and success in the industry ...
(Date:7/1/2015)... ... 2015 , ... With all final regulatory approvals in place ... N.Y., is now a member of national system Trinity Health, effective immediately. ... committed to delivering high-value care, said Richard J. Gilfillan, M.D., president and CEO, ...
(Date:7/1/2015)... ... 01, 2015 , ... For decades, researchers in the genetics field have theorized ... brain, never changing after development in the womb. Now, researchers from the Icahn School ... cells throughout life – a process which helps to switch genes on and off. ...
(Date:7/1/2015)... ... 01, 2015 , ... Ormco Corporation, a leading manufacturer and ... Smile for a Lifetime Foundation (S4L) fundraising event held at the 14th Annual ... S4L in its mission to provide free quality orthodontic care to individuals with ...
(Date:7/1/2015)... ... July 01, 2015 , ... The Collaborative for Children and ... Community Trust. The grant will allow CCF to improve quality of care and save ... was formed to respond to many changes in New York’s Medicaid system. Experts agree ...
Breaking Medicine News(10 mins):Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 2Health News:ColoradoBiz Magazine Names SlimGenics #14 on Top 100 Woman-Owned Companies List 3Health News:St. Joseph’s Health Now a Member of Trinity Health 2Health News:St. Joseph’s Health Now a Member of Trinity Health 3Health News:St. Joseph’s Health Now a Member of Trinity Health 4Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 2Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 3Health News:Mount Sinai Researchers Discover New Epigenetic Mechanism in Brain Cells 4Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 2Health News:The Forum Fundraiser Raises $80,000 for the Smile for a Lifetime Foundation 3Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3
... 02, 2009 The antiepileptic drug vigabatrin (VGB) has been ... special form of epilepsy in infants, called infantile spasm. However, ... has been shown to cause a permanent narrowing of visual ... exposed at school age or later. A new study published ...
... U.S. Ambassador to the United Republic of Tanzania, joins Malaria ... No More Policy Center in Washington, DC, the non-profit organization ... fight against malaria in Africa to his new role at ... advocacy work to engage policymakers in the race to save ...
... given awayFORT WORTH, Texas, Feb. 2 ... USA announces the launch of the second season ... 26, 2009, Marinela USA consumers can collect one ... specially marked boxes of Barritas Fresa, Barritas Pina, ...
... and only multi-module training program devoted exclusively to whiplash ... Stutzman, local Doctor of Chiropractic practicing in Paoli, PA ... specifically to whiplash and brain injury traumatology. The ... prestigious Spine Research Institute of San Diego . ...
... Danaher Corporation (NYSE: DHR ) announced ... L. Comas will be presenting at the Barclays Capital ... 9, 2009 at 1:35 p.m. EST. The audio will ... of the webcast will be available for one week ...
... Digirad Corporation (Nasdaq: DRAD ), a ... equipment leasing services that improve patient care while driving ... the assets related to three northern California service hub ... Fe, Calif.-based MD Office Solutions calls for the sale ...
Cached Medicine News:Health News:Controversial medication may decrease spasms for infants with epilepsy 2Health News:Recent U.S. Ambassador to Tanzania Mark Green Named Managing Director of Malaria No More Policy Center 2Health News:Marinela USA(R) Recharges ZumbAtomic for Second Season 2Health News:Local Chiropractic Doctor Graduates from Elite Whiplash Trauma Training Program Led by International Scientific Authority, Dr. Arthur Croft 2Health News:Local Chiropractic Doctor Graduates from Elite Whiplash Trauma Training Program Led by International Scientific Authority, Dr. Arthur Croft 3Health News:Digirad Corporation Sells Northern California Service Hubs 2
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
The Trident PSL Acetabular Shells are designed to maximize fixation in the peripheral lunate region of the acetabulum....
The Trident ceramic acetabular system provides several important benefits and meets greater demands of younger, more active patients....
Medicine Products: